Trial Profile
A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month schedule
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2007
Price :
$35
*
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors Berna Biotech
- 23 Apr 2007 New trial record.